GlassScriptPhysician profile
Eric G Davis
NPI 1154486744
$77,662.90
in general payments reported to CMS, 2019-2025
16 companies · $17K in 2025
The $17K reported for 2025 was more than what 95% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $161 · 2021: $31K · 2022: $18K · 2023: $9,263 · 2024: $2,682 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,500 · Travel and Lodging: $2,231 · Food and Beverage: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,149.90 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,500.00 |
| Travel and Lodging | $2,231.25 |
| Food and Beverage | $687.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $43,779.12 | 2021-2025 | Cd Horizon Spinal System, Mazor X System, Unid_pass |
| Stryker Corporation | $14,300.00 | 2021-2023 | Cascadia Interbody System |
| Expanding Innovations, INC. | $8,999.90 | 2025 | X-Pac |
| Nuvasive, INC. | $4,000.00 | 2022 | |
| Alphatec Spine, INC | $3,939.14 | 2022 | |
| Centinel Spine, LLC | $1,494.62 | 2025 | Prodisc L |
| Veloxis Pharmaceuticals, INC. | $484.80 | 2019-2022 | |
| Medtronic USA, INC. | $116.91 | 2020 | |
| Merck Sharp & Dohme LLC | $114.34 | 2024 | Prevymis |
| Genentech, INC. | $112.56 | 2023 | Tecentriq |
| Novartis Pharmaceuticals Corporation | $97.61 | 2019 | |
| Atricure, INC. | $97.35 | 2022 | |
| Abbvie INC. | $44.21 | 2022 | |
| Allergan, INC. | $37.77 | 2019 | |
| Exelixis INC. | $25.89 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $18.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,999.80 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.